Biotest AG
Karl Lauterbach visits Biotest AG’s plasma donation centre in Cologne and emphasises important contribution to patient care

PRESS RELEASE

Karl Lauterbach visits Biotest AG’s plasma donation centre in Cologne and emphasises important contribution to patient care

• Plasma donation in Germany secures the long-term supply of vital medicines for patients
• State-of-the-art plasma service centre opened in Cologne-Mülheim in January

Dreieich, 28 February 2024. Member of the German Bundestag Prof Dr Karl Lauterbach visited the most modern of the 11 Plasma Service centres in Germany at Wiener Platz in Cologne, which was newly opened in January 2024. The new centre is operated by Plasma Service Europe GmbH, a wholly owned subsidiary of Biotest AG, which was founded more than 20 years ago to strengthen plasma donation in Germany.

Medical Director Tanja Engelen gave a tour of the plasma donation centre and highlighted the paperless donation and the importance of plasma donation for medical care.

“Plasma donations save lives and are urgently needed. I would like to personally thank the many donors who are willing to make a contribution to the care of seriously ill patients for their commitment,” emphasised Prof Dr Karl Lauterbach in the donation room and also thanked the employees and management for their contribution to healthcare.

The situation is serious, as supplies in Germany are becoming increasingly scarce and demand is constantly rising. Worrying supply bottlenecks of preparations due to plasma shortages mean disaster for many patients: they have to fear for their vital medicines. In the European Union, for example, a shortfall of 22% in plasma collection has been forecast for 2021. This corresponds to a shortfall of around 2 million litres of plasma for the supply of plasma preparations.

“Germany is a good example of cooperation between public organisations and private companies in order to guarantee the nationwide supply of plasma. At European level, better protection of patients and donors will be regulated in future by the EU SoHO (Substances of Human Origin) Regulation, thus creating standardised competitive conditions,” said Peter Janssen, CEO of Biotest AG.

The collected plasma is processed exclusively in Germany at Biotest AG in Dreieich. Regular audits in Germany ensure that the high legal and internal quality and safety requirements are met.

About human blood plasma

Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world’s sixth largest plasma protein product manufacturing groups. Biotest is one of the world’s six largest manufacturers of plasma protein products.

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).

IR contact

Dr Monika Baumann (Buttkereit)

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.